Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2019.02.001
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2019
Authors
Publisher
Elsevier BV